Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Study to Evaluate the Efficacy and Safety of MEDI9929 (AMG 157) in Adult Subjects With Inadequately Controlled, Severe Asthma

5 de noviembre de 2018 actualizado por: MedImmune LLC

A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI9929 in Adult Subjects With Inadequately Controlled, Severe Asthma

The primary objective of the study is to evaluate the effect of 3 dose levels of MEDI9929 (AMG 157) on asthma exacerbations in adult subjects with inadequately controlled, severe asthma.

Descripción general del estudio

Estado

Terminado

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Actual)

584

Fase

  • Fase 2

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

  • Bulgaria
      • Plovdiv, Bulgaria, 4002
        • Research Site
      • Sofia, Bulgaria, 1431
        • Research Site
      • Sofia, Bulgaria, 1202
        • Research Site
      • Sofia, Bulgaria, 1233
        • Research Site
      • Sofia, Bulgaria, 1750
        • Research Site
      • Sofia, Bulgaria, 1606
        • Research Site
      • Velingrad, Bulgaria, 4600
        • Research Site
  • Chequia
      • Brandys nad Labem, Chequia, 250 01
        • Research Site
      • Hradec Kralove, Chequia, 500 05
        • Research Site
      • Mlada Boleslav, Chequia, 293 01
        • Research Site
      • Praha 4, Chequia, 14059
        • Research Site
      • Praha 8, Chequia, 180 81
        • Research Site
      • Praha 8, Chequia, 180 00
        • Research Site
      • Strakonice, Chequia, 38601
        • Research Site
  • Eslovaquia
      • Bardejov, Eslovaquia, 085 01
        • Research Site
      • Bratislava, Eslovaquia, 84108
        • Research Site
      • Ilava, Eslovaquia, 01901
        • Research Site
      • Kosice, Eslovaquia, 040 01
        • Research Site
      • Levice, Eslovaquia, 934 01
        • Research Site
      • Nove Zamky, Eslovaquia, 940 01
        • Research Site
      • Poprad, Eslovaquia, 058 01
        • Research Site
      • Spisska Nova Ves, Eslovaquia, 052 01
        • Research Site
      • Sturovo, Eslovaquia, 94301
        • Research Site
      • Surany, Eslovaquia, 94201
        • Research Site
      • Topolcany, Eslovaquia, 95501
        • Research Site
      • Zvolen, Eslovaquia, 96001
        • Research Site
  • Estados Unidos
    • California
      • Los Angeles, California, Estados Unidos, 90025
        • Research Site
      • Los Angeles, California, Estados Unidos, 90048
        • Research Site
    • Florida
      • Miami, Florida, Estados Unidos, 33133
        • Research Site
      • Oviedo, Florida, Estados Unidos, 32765
        • Research Site
    • Georgia
      • Savannah, Georgia, Estados Unidos, 31406
        • Research Site
    • Illinois
      • Peoria, Illinois, Estados Unidos, 61602
        • Research Site
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21224
        • Research Site
    • Minnesota
      • Rochester, Minnesota, Estados Unidos, 55905
        • Research Site
    • New York
      • New York, New York, Estados Unidos, 10016
        • Research Site
      • New York, New York, Estados Unidos, 10029
        • Research Site
    • North Carolina
      • Charlotte, North Carolina, Estados Unidos, 28277
        • Research Site
      • Charlotte, North Carolina, Estados Unidos, 28207
        • Research Site
    • Ohio
      • Dublin, Ohio, Estados Unidos, 43016
        • Research Site
    • Oklahoma
      • Oklahoma City, Oklahoma, Estados Unidos, 73120
        • Research Site
    • South Carolina
      • Rock Hill, South Carolina, Estados Unidos, 29732
        • Research Site
      • Spartanburg, South Carolina, Estados Unidos, 29303
        • Research Site
    • Texas
      • Houston, Texas, Estados Unidos, 77070
        • Research Site
    • Virginia
      • Richmond, Virginia, Estados Unidos, 23220
        • Research Site
  • Hungría
      • Balassagyarmat, Hungría, 2660
        • Research Site
      • Budapest, Hungría, 1125
        • Research Site
      • Budapest, Hungría, 1529
        • Research Site
      • Budapest, Hungría, 1033
        • Research Site
      • Csorna, Hungría, 9300
        • Research Site
      • Debrecen, Hungría, 4032
        • Research Site
      • Farkasgyepü, Hungría, 8582
        • Research Site
      • Gödöllő, Hungría, 2100
        • Research Site
      • Komarom, Hungría, 2900
        • Research Site
      • Mateszalka, Hungría, 4700
        • Research Site
      • Nagykanizsa, Hungría, 8800
        • Research Site
      • Szeged, Hungría, H-6722
        • Research Site
      • Százhalombatta, Hungría, 2440
        • Research Site
      • Torokbalint, Hungría, 2045
        • Research Site
  • Israel
      • Ashkelon, Israel, 78278
        • Research Site
      • Haifa, Israel, 34362
        • Research Site
      • Jerusalem, Israel, 91120
        • Research Site
      • Kfar-Saba, Israel, 44281
        • Research Site
      • Petach Tikva, Israel
        • Research Site
      • Rehovot, Israel, 7661041
        • Research Site
      • Tel Hashomer, Israel, 52621
        • Research Site
  • Japón
      • Chuo-ku, Japón, 103-0028
        • Research Site
      • Chuo-ku, Japón, 103-0027
        • Research Site
      • Chuo-ku, Japón, 104-8560
        • Research Site
      • Fujisawa-shi, Japón, 251-8550
        • Research Site
      • Kiyose-shi, Japón, 204-8585
        • Research Site
      • Kurume-shi, Japón, 830-0011
        • Research Site
      • Maebashi-shi, Japón, 371-0054
        • Research Site
      • Ora-gun, Japón, 370-0615
        • Research Site
      • Sagamihara-shi, Japón, 228-0815
        • Research Site
      • Saitama-Ken, Japón, 338-8553
        • Research Site
      • Sapporo-shi, Japón, 060-0033
        • Research Site
      • Taito-ku, Japón, 111-0051
        • Research Site
      • Toshima-ku, Japón, 171-0014
        • Research Site
      • Yokkaichi-shi, Japón, 510-8567
        • Research Site
  • Letonia
      • Daugavpils, Letonia, LV-5401
        • Research Site
      • Rezekne, Letonia, LV-4600
        • Research Site
      • Riga, Letonia, 1001
        • Research Site
      • Riga, Letonia, LV1002
        • Research Site
      • Riga, Letonia, LV-1038
        • Research Site
      • Riga, Letonia, LV1010
        • Research Site
  • Lituania
      • Kaunas, Lituania, LT50009
        • Research Site
      • Klaipeda, Lituania, 92288
        • Research Site
      • Klaipeda, Lituania, 92231
        • Research Site
  • Serbia
      • Belgrade, Serbia, 11000
        • Research Site
      • Kragujevac, Serbia, 34000
        • Research Site
      • Sremska Kamenica, Serbia, 21204
        • Research Site
  • Sudáfrica
      • Durban, Sudáfrica, 4068
        • Research Site
      • Middelburg, Sudáfrica, 1055
        • Research Site
      • Pretoria, Sudáfrica, 0181
        • Research Site
      • Pretoria, Sudáfrica, 0183
        • Research Site
  • Ucrania
      • Dnipropetrovsk, Ucrania, 49051
        • Research Site
      • Ivano-Frankivsk, Ucrania, 76012
        • Research Site
      • Kyiv, Ucrania, 04050
        • Research Site
      • Kyiv, Ucrania, 02091
        • Research Site
      • Kyiv, Ucrania, 03680
        • Research Site
      • Mykolayiv, Ucrania, 54003
        • Research Site
      • Odessa, Ucrania, 65039
        • Research Site
      • Poltava, Ucrania, 36038
        • Research Site
      • Suprunivka Vil., Poltava Regio, Ucrania, 36028
        • Research Site
      • Vinnytsia, Ucrania, 21029
        • Research Site
      • Zaporizhzhya, Ucrania, 69600
        • Research Site
      • Zaporizhzhya, Ucrania, 69035
        • Research Site

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 75 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Age 18 through 75
  • Body mass index (BMI) between 18-40 kg/m2 and weight greater than or equal 40 kg
  • Documented physician-diagnosed asthma - Subjects must have received a physician-prescribed asthma controller regimen with medium- or high-dose inhaled corticosteroids (ICS) plus long acting β2 agonist (LABA) -If on asthma controller medications in addition to ICS plus LABA, the dose of the other asthma controller medications (leukotriene receptor inhibitors, theophylline, secondary ICS, long-acting anti-muscarinics (LAMA), cromones, or maintenance oral prednisone or equivalent up to a maximum of 10 mg daily or 20 mg every other day for the maintenance treatment of asthma) must be stable. -Subjects must have a documented history of at least 2 asthma exacerbation events OR at least 1 severe asthma exacerbation resulting in hospitalization within the 12 months prior to first study visit.

Exclusion Criteria:

  • Diagnosis of vocal cord dysfunction, reactive airways dysfunction syndrome, hyperventilation and panic attacks, or other mimics of asthma.
  • Current smokers or subjects with a smoking history of ≥ 10 pack years
  • Former smokers with < 10 pack years must have stopped for at least 1 year to be eligible.
  • Any concomitant respiratory disease that in the opinion of the investigator and/or medical monitor will interfere with the evaluation of the investigational product or interpretation of subject safety or study results (eg, chronic obstructive pulmonary disease, cystic fibrosis, pulmonary fibrosis, bronchiectasis, allergic bronchopulmonary aspergillosis, Churg-Strauss syndrome).
  • Evidence of active liver disease.
  • History of Cancer, except for basal cell carcinoma or insitu carcinoma of the cervix treated with apparent success with curative therapy or other malignancies are eligible provided that curative therapy was completed -Known history of active tuberculosis (TB)
  • History of anaphylaxis to any biologic therapy
  • Positive medical history for hepatitis B or C
  • Subject with human immunodeficiency virus (HIV) or subject taking antiretroviral medications, as determined by medical history and/or subject's verbal report.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador de placebos: Placebo
Participants received placebo matched to MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
Droga: Placebo
Participants received placebo matched to MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
Experimental: MEDI9929 70 mg
Participants received 70 milligram (mg) of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
Droga: MEDI9929 70 mg
Participants received 70 milligram (mg) of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
Experimental: MEDI9929 210 mg
Participants received 210 mg of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
Droga: MEDI9929 210 mg
Participants received 210 mg of MEDI9929 subcutaneously once every 4 weeks from Day 1 to Week 48 along with subcutaneous placebo once every 4 weeks from Week 2 to Week 50.
Experimental: MEDI9929 280 mg
Participants received 280 mg of MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.
Droga: MEDI9929 280 mg
Participants received 280 mg of MEDI9929 subcutaneously once every 2 weeks from Day 1 to Week 50.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Annualized Asthma Exacerbation Rate (AER) Through Week 52
Periodo de tiempo: Week 0 (Day 1) up to Week 52
Asthma exacerbation is defined as worsening of asthma that leads to any of the following: use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. The annual AER was presented as the total number of exacerbations for the treatment group divided by the total duration of person follow-up.
Week 0 (Day 1) up to Week 52

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Reduction in AER on Subpopulations at Week 52
Periodo de tiempo: Week 52
Asthma exacerbation is defined as worsening of asthma that leads to any of the following: use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. Reduction in AER was evaluated in pre-specified subpopulations (blood eosinophil count [eosinophilic and non-eosinophilic], T helper cell 2 [Th2] status [high and low], Fraction of exhaled nitric oxide [FENO] [high and low], serum periostin [high and low], current post bronchodilator forced expiratory volume in 1 second [Post-BD FEV1] reversibility- yes, allergic and non-allergic) of asthma. The annual AER was presented as the total number of exacerbations for the treatment group divided by the total duration of person follow-up. Also, the high or low was determined using median value.
Week 52
Change From Baseline in Pre-bronchodilator (Pre-BD) Forced Expiratory Volume in 1 Second (FEV1) and Forced Vital Capacity (FVC) at Week 52
Periodo de tiempo: Baseline (Week 0 [Day 1]) to Week 52
Forced expiratory volume in 1 second and forced vital capacity measures taken before bronchodilator use were reported.
Baseline (Week 0 [Day 1]) to Week 52
Change From Baseline in FEV1 on Subpopulations at Week 52
Periodo de tiempo: Baseline and up to Week 52
Forced expiratory volume in one second (FEV1) was evaluated in pre-specified subpopulations of asthma. The data presented in the below table for this outcome measure is for pre-bronchodilator FEV1.
Baseline and up to Week 52
Change From Baseline in Post-bronchodilator (Post-BD) FEV1 and FVC at Week 52
Periodo de tiempo: Baseline (Week 0 [Day 1]) to Week 52
Forced expiratory volume in 1 second and forced vital capacity measures taken after bronchodilator use were reported.
Baseline (Week 0 [Day 1]) to Week 52
Change From Baseline in Overall Symptoms Score on Subpopulations at Week 52
Periodo de tiempo: Baseline and up to Week 52
Asthma symptoms during night time and daytime are recorded by the participant in the asthma daily diary. Overall symptom score is the average of scores of daytime severity, daytime frequency, and nighttime severity symptoms. The daytime frequency and severity items are scored from 0 to 4, where a higher score indicates greater frequency/severity and nighttime severity item is scored from 0 to 4 , where a higher score indicates greater severity. Overall symptom score ranges from 0 to 4, where lower score indicates better asthma symptom while, higher score indicates worse asthma symptom.
Baseline and up to Week 52
Change From Baseline in Asthma Symptoms Measured by Asthma Daily Diary at Week 52
Periodo de tiempo: Baseline (Week 0 [Day 1]) and Week 52
Asthma symptoms during night time and daytime are recorded by the participant in the asthma daily diary. Symptom score values for night time assessment is 0 (no asthma symptom) to 3 (unable to sleep because of asthma) and symptom score values for day time assessment is 0 (no asthma symptom) to 3 (unable to do normal activities due to asthma). Total asthma symptom score is the sum of the daytime and night time score (0 to 6). Lower score (0) is indicating better asthma symptom, while higher score (6) is indicating worse asthma symptom.
Baseline (Week 0 [Day 1]) and Week 52
Change From Baseline in Asthma Symptoms Measured by Asthma Control Questionnaire (ACQ-6) Score at Week 52
Periodo de tiempo: Baseline (Week 0 [Day 1]) and Week 52
The ACQ is a patient-reported questionnaire assessing asthma symptoms (ie, night-time waking, symptoms on waking, activity limitation, shortness of breath, wheezing) and daily rescue bronchodilator use and FEV1. The ACQ-6 is a shortened version of the ACQ that omits the FEV1 measurement from the original ACQ score. Questions are weighted equally and scored from 0 (totally controlled) to 6 (severely uncontrolled).
Baseline (Week 0 [Day 1]) and Week 52
Rate of Severe Asthma Exacerbation Through Week 52
Periodo de tiempo: Week 0 (Day 1) up to Week 52
A severe asthma exacerbation is defined as an event that resulted in hospitalization. The severe AER was presented as the total number of exacerbations for the treatment group divided by the total duration of person follow-up.
Week 0 (Day 1) up to Week 52
Time to First Asthma Exacerbation Through Week 52
Periodo de tiempo: Week 0 (Day 1) through Week 52
Asthma exacerbation is defined as worsening of asthma that leads to use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. Time to first asthma exacerbation was reported.
Week 0 (Day 1) through Week 52
Time to First Severe Asthma Exacerbation Through Week 52
Periodo de tiempo: Week 0 (Day 1) through Week 52
Asthma exacerbation is defined as worsening of asthma that leads to use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. Time to first severe asthma exacerbations (hospitalization) were reported.
Week 0 (Day 1) through Week 52
Number of Participants With at Least One Asthma Exacerbations Through Week 52
Periodo de tiempo: Week 0 (Day 1) through Week 52
Asthma exacerbation is defined as worsening of asthma that leads to use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma.
Week 0 (Day 1) through Week 52
Number of Participants With at Least One Severe Asthma Exacerbations Through Week 52
Periodo de tiempo: Week 0 (Day 1) through Week 52
Asthma exacerbation is defined as worsening of asthma that leads to use of systemic corticosteroids for at least 3 days, an emergency department visit due to asthma that required systemic corticosteroids, and an inpatient hospitalization due to asthma. Participants with severe asthma exacerbations (hospitalization) were reported.
Week 0 (Day 1) through Week 52
Change From Baseline in Asthma Quality of Life Questionnaire (Standardized Version) (AQLQ [S]) Overall Score at Week 52
Periodo de tiempo: Baseline (Week 0 [Day 1]) and Week 52
The AQLQ(S) +12 is a 32-item questionnaire that measures the health-related quality of life experienced by asthma participants. The questionnaire comprises 4 separate domains (symptoms, activity limitations, emotional function, and environmental stimuli) scaled on a 7-point scale ranging from 7 (no impairment) to 1 (severe impairment).
Baseline (Week 0 [Day 1]) and Week 52
Change From Baseline in European Quality of Life-5 Dimensions 5 Level Version (EQ-5D-5L) Health State Evaluation at Week 52
Periodo de tiempo: Baseline (Week 0 [Day 1]) and Week 52
European Quality of Life-5 Dimensions-5 Level (EQ-5D-5L) is a standardized measure of health status of the participant. The first component is a descriptive system of the respondent's health comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The responses are used to derive the health state index scores using the United Kingdom (UK) algorithm, with scores ranging from -0.594 to 1. A higher score indicates better health state. The second component is a self-perceived health score which is assessed using a visual analogue scale (VAS) that ranged from 0 to 100, where 0 indicated the worst health you can imagine and 100 indicated the best health you can imagine.
Baseline (Week 0 [Day 1]) and Week 52
Total Amount of Study Drug Exposure
Periodo de tiempo: Week 0 (Day 1) through Week 52
The total amount of study drug exposure (in milligram) for the entire study period was summarized.
Week 0 (Day 1) through Week 52
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
Periodo de tiempo: Day 1 upto Week 64
An adverse event is any unfavourable and unintended signs (including abnormal laboratory findings), symptoms, or diseases temporally associated with use of medicinal product, whether or not considered related to medicinal product. Serious adverse event is any adverse event that resulted in death, life-threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAEs are defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug, for the period until and including the follow-up period (Week 64).
Day 1 upto Week 64
Number of Participants With TEAEs Related to Vital Sign Parameters
Periodo de tiempo: Day 1 upto Week 64
Adverse events observed in participants with clinically significant vital signs abnormalities were assessed.
Day 1 upto Week 64
Number of Participants With TEAEs Related to Clinical Laboratory Evaluation
Periodo de tiempo: Day 1 upto Week 64
An abnormal laboratory finding which required an action or intervention by the investigator, or a finding judged by the investigator to represent a change beyond the range of normal physiologic fluctuation were reported as an adverse event. Laboratory evaluations of blood and urine samples were performed.
Day 1 upto Week 64
Number of Participants With TEAEs Related to Electrocardiogram Evaluations
Periodo de tiempo: From the start of study drug administration upto Week 64
Adverse events observed in participants with clinically significant electrocardiogram abnormalities were assessed.
From the start of study drug administration upto Week 64
Mean Serum Concentrations of MEDI9929
Periodo de tiempo: Week 0 (Day 1) to Week 64
The mean serum concentrations of MEDI9929 was observed at specified timepoints.
Week 0 (Day 1) to Week 64
Number of Participants With Positive Antibodies to MEDI9929
Periodo de tiempo: Week 0 (Day 1) to Week 64
Blood samples for immunogenicity assessment included the determination of anti-drug antibodies (ADA) for MEDI9929. The number of participants with positive serum antibodies to MEDI9929 were presented.
Week 0 (Day 1) to Week 64

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

MedImmune LLC

Colaboradores

Amgen

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Enlaces Útiles

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

13 de diciembre de 2013

Finalización primaria (Actual)

12 de diciembre de 2016

Finalización del estudio (Actual)

1 de marzo de 2017

Fechas de registro del estudio

Enviado por primera vez

4 de diciembre de 2013

Primero enviado que cumplió con los criterios de control de calidad

3 de febrero de 2014

Publicado por primera vez (Estimar)

4 de febrero de 2014

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

4 de diciembre de 2018

Última actualización enviada que cumplió con los criterios de control de calidad

5 de noviembre de 2018

Última verificación

1 de noviembre de 2018

Más información

Términos relacionados con este estudio

Palabras clave

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • CD-RI-MEDI9929-1146
  • 2013-003269-33 (Número EudraCT)

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir